Nanomedicine Market by Modality, Application, and Indication: Global Opportunity Analysis and Industry Forecast, 2021-2030

Table of Contents

Chapter 1: Introduction
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models

Chapter 2: Executive Summary
2.1. Cxo Perspective

Chapter 3: Market Landscape
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power Among Buyers
3.4. Market Share Analysis/Top Player Positioning
3.4.1. Market Share Analysis/Top Player Positioning 2020
3.5. Market Dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. Covid-19 Impact Analysis

Chapter 4: Nanomedicine Market, by Application
4.1. Market Overview
4.1.1Market Size and Forecast, by Application
4.2. Drug Delivery
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, by Region
4.2.3. Market Share Analysis, by Country
4.3. Diagnostic Imaging
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, by Region
4.3.3. Market Share Analysis, by Country
4.4. Regenerative Medicine
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, by Region
4.4.3. Market Share Analysis, by Country
4.5. Implants
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.5.2. Market Size and Forecast, by Region
4.5.3. Market Share Analysis, by Country
4.6. Vaccines
4.6.1. Key Market Trends, Growth Factors and Opportunities
4.6.2. Market Size and Forecast, by Region
4.6.3. Market Share Analysis, by Country
4.7. Others
4.7.1. Key Market Trends, Growth Factors and Opportunities
4.7.2. Market Size and Forecast, by Region
4.7.3. Market Share Analysis, by Country

Chapter 5: Nanomedicine Market, by Indication
5.1. Market Overview
5.1.1Market Size and Forecast, by Indication
5.2. Clinical Oncology
5.2.1. Market Size and Forecast, by Region
5.2.2. Market Share Analysis, by Country
5.3. Infectious Diseases
5.3.1. Market Size and Forecast, by Region
5.3.2. Market Share Analysis, by Country
5.4. Clinical Cardiology
5.4.1. Market Size and Forecast, by Region
5.4.2. Market Share Analysis, by Country
5.5. Orthopedics
5.5.1. Market Size and Forecast, by Region
5.5.2. Market Share Analysis, by Country
5.6. Neurology
5.6.1. Market Size and Forecast, by Region
5.6.2. Market Share Analysis, by Country
5.7. Urology
5.7.1. Market Size and Forecast, by Region
5.7.2. Market Share Analysis, by Country
5.8. Ophthalmology
5.8.1. Market Size and Forecast, by Region
5.8.2. Market Share Analysis, by Country
5.9. Immunology
5.9.1. Market Size and Forecast, by Region
5.9.2. Market Share Analysis, by Country
5.10. Others
5.10.1. Market Size and Forecast, by Region
5.10.2. Market Share Analysis, by Country

Chapter 6: Nanomedicine Market, by Modality
6.1. Market Overview
6.1.1. Market Size and Forecast, by Modality
6.2. Treatments
6.2.1. Market Size and Forecast, by Region
6.2.2. Market Share Analysis, by Country
6.3. Diagnostics
6.3.1. Market Size and Forecast, by Region
6.3.2. Market Share Analysis, by Country

Chapter 7: Nanomedicine Market, by Region
7.1. Market Overview
7.1.1Market Size and Forecast, by Region
7.2. North America
7.2.1. Key Market Trends and Opportunities
7.2.2. Market Size and Forecast, by Application
7.2.3. Market Size and Forecast, by Indication
7.2.4. Market Size and Forecast, by Modality
7.2.5. Market Size and Forecast, by Country
7.2.6. United States Nanomedicine Market
7.2.6.1. Market Size and Forecast, by Application
7.2.6.2. Market Size and Forecast, by Indication
7.2.6.3. Market Size and Forecast, by Modality
7.2.7. Canada Nanomedicine Market
7.2.7.1. Market Size and Forecast, by Application
7.2.7.2. Market Size and Forecast, by Indication
7.2.7.3. Market Size and Forecast, by Modality
7.2.8. Mexico Nanomedicine Market
7.2.8.1. Market Size and Forecast, by Application
7.2.8.2. Market Size and Forecast, by Indication
7.2.8.3. Market Size and Forecast, by Modality
7.3. Europe
7.3.1. Key Market Trends and Opportunities
7.3.2. Market Size and Forecast, by Application
7.3.3. Market Size and Forecast, by Indication
7.3.4. Market Size and Forecast, by Modality
7.3.5. Market Size and Forecast, by Country
7.3.6. Germany Nanomedicine Market
7.3.6.1. Market Size and Forecast, by Application
7.3.6.2. Market Size and Forecast, by Indication
7.3.6.3. Market Size and Forecast, by Modality
7.3.7. France Nanomedicine Market
7.3.7.1. Market Size and Forecast, by Application
7.3.7.2. Market Size and Forecast, by Indication
7.3.7.3. Market Size and Forecast, by Modality
7.3.8. UK Nanomedicine Market
7.3.8.1. Market Size and Forecast, by Application
7.3.8.2. Market Size and Forecast, by Indication
7.3.8.3. Market Size and Forecast, by Modality
7.3.9. Italy Nanomedicine Market
7.3.9.1. Market Size and Forecast, by Application
7.3.9.2. Market Size and Forecast, by Indication
7.3.9.3. Market Size and Forecast, by Modality
7.3.10. Spain Nanomedicine Market
7.3.10.1. Market Size and Forecast, by Application
7.3.10.2. Market Size and Forecast, by Indication
7.3.10.3. Market Size and Forecast, by Modality
7.3.11. Rest of Europe Nanomedicine Market
7.3.11.1. Market Size and Forecast, by Application
7.3.11.2. Market Size and Forecast, by Indication
7.3.11.3. Market Size and Forecast, by Modality
7.4. Asia-Pacific
7.4.1. Key Market Trends and Opportunities
7.4.2. Market Size and Forecast, by Application
7.4.3. Market Size and Forecast, by Indication
7.4.4. Market Size and Forecast, by Modality
7.4.5. Market Size and Forecast, by Country
7.4.6. Japan Nanomedicine Market
7.4.6.1. Market Size and Forecast, by Application
7.4.6.2. Market Size and Forecast, by Indication
7.4.6.3. Market Size and Forecast, by Modality
7.4.7. China Nanomedicine Market
7.4.7.1. Market Size and Forecast, by Application
7.4.7.2. Market Size and Forecast, by Indication
7.4.7.3. Market Size and Forecast, by Modality
7.4.8. Australia Nanomedicine Market
7.4.8.1. Market Size and Forecast, by Application
7.4.8.2. Market Size and Forecast, by Indication
7.4.8.3. Market Size and Forecast, by Modality
7.4.9. India Nanomedicine Market
7.4.9.1. Market Size and Forecast, by Application
7.4.9.2. Market Size and Forecast, by Indication
7.4.9.3. Market Size and Forecast, by Modality
7.4.10. South Korea Nanomedicine Market
7.4.10.1. Market Size and Forecast, by Application
7.4.10.2. Market Size and Forecast, by Indication
7.4.10.3. Market Size and Forecast, by Modality
7.4.11. Rest of Asia-Pacific Nanomedicine Market
7.4.11.1. Market Size and Forecast, by Application
7.4.11.2. Market Size and Forecast, by Indication
7.4.11.3. Market Size and Forecast, by Modality
7.5. Lamea
7.5.1. Key Market Trends and Opportunities
7.5.2. Market Size and Forecast, by Application
7.5.3. Market Size and Forecast, by Indication
7.5.4. Market Size and Forecast, by Modality
7.5.5. Market Size and Forecast, by Country
7.5.6. Brazil Nanomedicine Market
7.5.6.1. Market Size and Forecast, by Application
7.5.6.2. Market Size and Forecast, by Indication
7.5.6.3. Market Size and Forecast, by Modality
7.5.7. Saudi Arabia Nanomedicine Market
7.5.7.1. Market Size and Forecast, by Application
7.5.7.2. Market Size and Forecast, by Indication
7.5.7.3. Market Size and Forecast, by Modality
7.5.8. South Africa Nanomedicine Market
7.5.8.1. Market Size and Forecast, by Application
7.5.8.2. Market Size and Forecast, by Indication
7.5.8.3. Market Size and Forecast, by Modality
7.5.9. Rest of LAMEA Nanomedicine Market
7.5.9.1. Market Size and Forecast, by Application
7.5.9.2. Market Size and Forecast, by Indication
7.5.9.3. Market Size and Forecast, by ModalityChapter 8: Company Profiles
8.1. Abbott Laboratories
8.1.1. Company Overview
8.1.2. Key Executives
8.1.3. Company Snapshot
8.1.4. Operating Business Segments
8.1.5. Product Portfolio
8.1.6. Business Performance
8.1.7. Key Strategic Moves and Developments
8.2. Diasorin S. P. A.
8.2.1. Company Overview
8.2.2. Key Executives
8.2.3. Company Snapshot
8.2.4. Operating Business Segments
8.2.5. Product Portfolio
8.2.6. Business Performance
8.2.7. Key Strategic Moves and Developments
8.3. General Electric Company
8.3.1. Company Overview
8.3.2. Key Executives
8.3.3. Company Snapshot
8.3.4. Operating Business Segments
8.3.5. Product Portfolio
8.3.6. Business Performance
8.3.7. Key Strategic Moves and Developments
8.4. Invitae Corporation
8.4.1. Company Overview
8.4.2. Key Executives
8.4.3. Company Snapshot
8.4.4. Operating Business Segments
8.4.5. Product Portfolio
8.4.6. Business Performance
8.4.7. Key Strategic Moves and Developments
8.5. Johnson & Johnson
8.5.1. Company Overview
8.5.2. Key Executives
8.5.3. Company Snapshot
8.5.4. Operating Business Segments
8.5.5. Product Portfolio
8.5.6. Business Performance
8.5.7. Key Strategic Moves and Developments
8.6. Leadiant Biosciences, Inc.
8.6.1. Company Overview
8.6.2. Key Executives
8.6.3. Company Snapshot
8.6.4. Operating Business Segments
8.6.5. Product Portfolio
8.6.6. Business Performance
8.6.7. Key Strategic Moves and Developments
8.7. Mallinckrodt plc
8.7.1. Company Overview
8.7.2. Key Executives
8.7.3. Company Snapshot
8.7.4. Operating Business Segments
8.7.5. Product Portfolio
8.7.6. Business Performance
8.7.7. Key Strategic Moves and Developments
8.8. Merck & Co. Inc.
8.8.1. Company Overview
8.8.2. Key Executives
8.8.3. Company Snapshot
8.8.4. Operating Business Segments
8.8.5. Product Portfolio
8.8.6. Business Performance
8.8.7. Key Strategic Moves and Developments
8.9. Pfizer, Inc.
8.9.1. Company Overview
8.9.2. Key Executives
8.9.3. Company Snapshot
8.9.4. Operating Business Segments
8.9.5. Product Portfolio
8.9.6. Business Performance
8.9.7. Key Strategic Moves and Developments
8.10. Teva Pharmaceutical Industries Limited
8.10.1. Company Overview
8.10.2. Key Executives
8.10.3. Company Snapshot
8.10.4. Operating Business Segments
8.10.5. Product Portfolio
8.10.6. Business Performance
8.10.7. Key Strategic Moves and Developments

List of Tables
List of Tables
Table 1. Global Nanomedicine Market, by Application, 2020-2030 ($Million)
Table 2. Global Nanomedicine Market for Drug Delivery, by Region, 2020-2030 ($Million)
Table 3. Global Nanomedicine Market for Diagnostic Imaging, by Region, 2020-2030 ($Million)
Table 4. Global Nanomedicine Market for Regenerative Medicine, by Region, 2020-2030 ($Million)
Table 5. Global Nanomedicine Market for Implants, by Region, 2020-2030 ($Million)
Table 6. Global Nanomedicine Market for Vaccines, by Region, 2020-2030 ($Million)
Table 7. Global Nanomedicine Market for Others, by Region, 2020-2030 ($Million)
Table 8. Global Nanomedicine Market, by Indication, 2020-2030 ($Million)
Table 9. Global Nanomedicine Market for Clinical Oncology, by Region, 2020-2030 ($Million)
Table 10. Global Nanomedicine Market for Infectious Diseases, by Region, 2020-2030 ($Million)
Table 11. Global Nanomedicine Market for Clinical Cardiology, by Region, 2020-2030 ($Million)
Table 12. Global Nanomedicine Market for Orthopedics, by Region, 2020-2030 ($Million)
Table 13. Global Nanomedicine Market for Neurology, by Region, 2020-2030 ($Million)
Table 14. Global Nanomedicine Market for Urology, by Region, 2020-2030 ($Million)
Table 15. Global Nanomedicine Market for Ophthalmology, by Region, 2020-2030 ($Million)
Table 16. Global Nanomedicine Market for Immunology, by Region, 2020-2030 ($Million)
Table 17. Global Nanomedicine Market for Others, by Region, 2020-2030 ($Million)
Table 18. Global Nanomedicine Market, by Modality, 2020-2030 ($Million)
Table 19. Global Nanomedicine Market for Treatments, by Region, 2020-2030 ($Million)
Table 20. Global Nanomedicine Market for Diagnostics, by Region, 2020-2030 ($Million)
Table 21. Global Nanomedicine Market, by Region, 2020-2030 ($Million)
Table 22. North America Nanomedicine, by Application, 2020-2030 ($Million)
Table 23. North America Nanomedicine, by Indication, 2020-2030 ($Million)
Table 24. North America Nanomedicine, by Modality, 2020-2030 ($Million)
Table 25. United States Nanomedicine, by Application, 2020-2030 ($Million)
Table 26. United States Nanomedicine, by Indication, 2020-2030 ($Million)
Table 27. United States Nanomedicine, by Modality, 2020-2030 ($Million)
Table 28. Canada Nanomedicine, by Application, 2020-2030 ($Million)
Table 29. Canada Nanomedicine, by Indication, 2020-2030 ($Million)
Table 30. Canada Nanomedicine, by Modality, 2020-2030 ($Million)
Table 31. Mexico Nanomedicine, by Application, 2020-2030 ($Million)
Table 32. Mexico Nanomedicine, by Indication, 2020-2030 ($Million)
Table 33. Mexico Nanomedicine, by Modality, 2020-2030 ($Million)
Table 34. Europe Nanomedicine, by Application, 2020-2030 ($Million)
Table 35. Europe Nanomedicine, by Indication, 2020-2030 ($Million)
Table 36. Europe Nanomedicine, by Modality, 2020-2030 ($Million)
Table 37. Germany Nanomedicine, by Application, 2020-2030 ($Million)
Table 38. Germany Nanomedicine, by Indication, 2020-2030 ($Million)
Table 39. Germany Nanomedicine, by Modality, 2020-2030 ($Million)
Table 40. France Nanomedicine, by Application, 2020-2030 ($Million)
Table 41. France Nanomedicine, by Indication, 2020-2030 ($Million)
Table 42. France Nanomedicine, by Modality, 2020-2030 ($Million)
Table 43. Uk Nanomedicine, by Application, 2020-2030 ($Million)
Table 44. Uk Nanomedicine, by Indication, 2020-2030 ($Million)
Table 45. Uk Nanomedicine, by Modality, 2020-2030 ($Million)
Table 46. Italy Nanomedicine, by Application, 2020-2030 ($Million)
Table 47. Italy Nanomedicine, by Indication, 2020-2030 ($Million)
Table 48. Italy Nanomedicine, by Modality, 2020-2030 ($Million)
Table 49. Spain Nanomedicine, by Application, 2020-2030 ($Million)
Table 50. Spain Nanomedicine, by Indication, 2020-2030 ($Million)
Table 51. Spain Nanomedicine, by Modality, 2020-2030 ($Million)
Table 52. Rest of Europe Nanomedicine, by Application, 2020-2030 ($Million)
Table 53. Rest of Europe Nanomedicine, by Indication, 2020-2030 ($Million)
Table 54. Rest of Europe Nanomedicine, by Modality, 2020-2030 ($Million)
Table 55. Asia-Pacific Nanomedicine, by Application, 2020-2030 ($Million)
Table 56. Asia-Pacific Nanomedicine, by Indication, 2020-2030 ($Million)
Table 57. Asia-Pacific Nanomedicine, by Modality, 2020-2030 ($Million)
Table 58. Japan Nanomedicine, by Application, 2020-2030 ($Million)
Table 59. Japan Nanomedicine, by Indication, 2020-2030 ($Million)
Table 60. Japan Nanomedicine, by Modality, 2020-2030 ($Million)
Table 61. China Nanomedicine, by Application, 2020-2030 ($Million)
Table 62. China Nanomedicine, by Indication, 2020-2030 ($Million)
Table 63. China Nanomedicine, by Modality, 2020-2030 ($Million)
Table 64. Australia Nanomedicine, by Application, 2020-2030 ($Million)
Table 65. Australia Nanomedicine, by Indication, 2020-2030 ($Million)
Table 66. Australia Nanomedicine, by Modality, 2020-2030 ($Million)
Table 67. India Nanomedicine, by Application, 2020-2030 ($Million)
Table 68. India Nanomedicine, by Indication, 2020-2030 ($Million)
Table 69. India Nanomedicine, by Modality, 2020-2030 ($Million)
Table 70. South Korea Nanomedicine, by Application, 2020-2030 ($Million)
Table 71. South Korea Nanomedicine, by Indication, 2020-2030 ($Million)
Table 72. South Korea Nanomedicine, by Modality, 2020-2030 ($Million)
Table 73. Rest of Asia-Pacific Nanomedicine, by Application, 2020-2030 ($Million)
Table 74. Rest of Asia-Pacific Nanomedicine, by Indication, 2020-2030 ($Million)
Table 75. Rest of Asia-Pacific Nanomedicine, by Modality, 2020-2030 ($Million)
Table 76. Lamea Nanomedicine, by Application, 2020-2030 ($Million)
Table 77. Lamea Nanomedicine, by Indication, 2020-2030 ($Million)
Table 78. Lamea Nanomedicine, by Modality, 2020-2030 ($Million)
Table 79. Brazil Nanomedicine, by Application, 2020-2030 ($Million)
Table 80. Brazil Nanomedicine, by Indication, 2020-2030 ($Million)
Table 81. Brazil Nanomedicine, by Modality, 2020-2030 ($Million)
Table 82. Saudi Arabia Nanomedicine, by Application, 2020-2030 ($Million)
Table 83. Saudi Arabia Nanomedicine, by Indication, 2020-2030 ($Million)
Table 84. Saudi Arabia Nanomedicine, by Modality, 2020-2030 ($Million)
Table 85. South Africa Nanomedicine, by Application, 2020-2030 ($Million)
Table 86. South Africa Nanomedicine, by Indication, 2020-2030 ($Million)
Table 87. South Africa Nanomedicine, by Modality, 2020-2030 ($Million)
Table 88. Rest of LAMEA Nanomedicine, by Application, 2020-2030 ($Million)
Table 89. Rest of LAMEA Nanomedicine, by Indication, 2020-2030 ($Million)
Table 90. Rest of LAMEA Nanomedicine, by Modality, 2020-2030 ($Million)
Table 91. Abbott Laboratories: Key Executives
Table 92. Abbott Laboratories: Company Snapshot
Table 93. Abbott Laboratories: Operating Segments
Table 94. Abbott Laboratories: Product Portfolio
Table 95. Abbott Laboratories: Key Strategic Moves and Developments
Table 96. Diasorin S. P. A. : Key Executives
Table 97. Diasorin S. P. A. : Company Snapshot
Table 98. Diasorin S. P. A. : Operating Segments
Table 99. Diasorin S. P. A. : Product Portfolio
Table 100. Diasorin S. P. A. : Key Strategic Moves and Developments
Table 101. General Electric Company: Key Executives
Table 102. General Electric Company: Company Snapshot
Table 103. General Electric Company: Operating Segments
Table 104. General Electric Company: Product Portfolio
Table 105. General Electric Company: Key Strategic Moves and Developments
Table 106. Invitae Corporation: Key Executives
Table 107. Invitae Corporation: Company Snapshot
Table 108. Invitae Corporation: Operating Segments
Table 109. Invitae Corporation: Product Portfolio
Table 110. Invitae Corporation: Key Strategic Moves and Developments
Table 111. Johnson & Johnson: Key Executives
Table 112. Johnson & Johnson: Company Snapshot
Table 113. Johnson & Johnson: Operating Segments
Table 114. Johnson & Johnson: Product Portfolio
Table 115. Johnson & Johnson: Key Strategic Moves and Developments
Table 116. Leadiant Biosciences, Inc. : Key Executives
Table 117. Leadiant Biosciences, Inc. : Company Snapshot
Table 118. Leadiant Biosciences, Inc. : Operating Segments
Table 119. Leadiant Biosciences, Inc. : Product Portfolio
Table 120. Leadiant Biosciences, Inc. : Key Strategic Moves and Developments
Table 121. Mallinckrodt plc: Key Executives
Table 122. Mallinckrodt plc: Company Snapshot
Table 123. Mallinckrodt plc: Operating Segments
Table 124. Mallinckrodt plc: Product Portfolio
Table 125. Mallinckrodt plc: Key Strategic Moves and Developments
Table 126. Merck & Co. Inc. : Key Executives
Table 127. Merck & Co. Inc. : Company Snapshot
Table 128. Merck & Co. Inc. : Operating Segments
Table 129. Merck & Co. Inc. : Product Portfolio
Table 130. Merck & Co. Inc. : Key Strategic Moves and Developments
Table 131. Pfizer, Inc. : Key Executives
Table 132. Pfizer, Inc. : Company Snapshot
Table 133. Pfizer, Inc. : Operating Segments
Table 134. Pfizer, Inc. : Product Portfolio
Table 135. Pfizer, Inc. : Key Strategic Moves and Developments
Table 136. Teva Pharmaceutical Industries Limited: Key Executives
Table 137. Teva Pharmaceutical Industries Limited: Company Snapshot
Table 138. Teva Pharmaceutical Industries Limited: Operating Segments
Table 139. Teva Pharmaceutical Industries Limited: Product Portfolio
Table 140. Teva Pharmaceutical Industries Limited: Key Strategic Moves and Developments

List of Figures
Figure 1. Global Nanomedicine Market Segmentation
Figure 2. Global Nanomedicine Market
Figure 3. Segmentation Nanomedicine Market
Figure 4. Top Investment Pocket in Nanomedicine Market
Figure 5. Top Winning Strategies, 2019-2021*
Figure 6. Top Winning Strategies, by Development, 2019-2021(%)
Figure 7. Top Winning Strategies, by Company, 2019-2021*
Figure 8. Moderate Bargaining Power of Buyers
Figure 9. Moderate Bargaining Power of Suppliers
Figure 10. Moderate Threat of New Entrants
Figure 11. Low Threat of Substitution
Figure 12. High Competitive Rivalry
Figure 13. Top Player Positioning, 2020
Figure 14. Market Share Analysis, 2020
Figure 15. Restraints and Drivers: Nanomedicine Market
Figure 16. Nanomedicine Market Segmentation, by Application
Figure 17. Nanomedicine Market for Drug Delivery, by Country, 2020-2030 ($ Million)
Figure 18. Nanomedicine Market for Diagnostic Imaging, by Country, 2020-2030 ($ Million)
Figure 19. Nanomedicine Market for Regenerative Medicine, by Country, 2020-2030 ($ Million)
Figure 20. Nanomedicine Market for Implants, by Country, 2020-2030 ($ Million)
Figure 21. Nanomedicine Market for Vaccines, by Country, 2020-2030 ($ Million)
Figure 22. Nanomedicine Market for Others, by Country, 2020-2030 ($ Million)
Figure 23. Nanomedicine Market Segmentation, by Indication
Figure 24. Nanomedicine Market for Clinical Oncology, by Country, 2020-2030 ($ Million)
Figure 25. Nanomedicine Market for Infectious Diseases, by Country, 2020-2030 ($ Million)
Figure 26. Nanomedicine Market for Clinical Cardiology, by Country, 2020-2030 ($ Million)
Figure 27. Nanomedicine Market for Orthopedics, by Country, 2020-2030 ($ Million)
Figure 28. Nanomedicine Market for Neurology, by Country, 2020-2030 ($ Million)
Figure 29. Nanomedicine Market for Urology, by Country, 2020-2030 ($ Million)
Figure 30. Nanomedicine Market for Ophthalmology, by Country, 2020-2030 ($ Million)
Figure 31. Nanomedicine Market for Immunology, by Country, 2020-2030 ($ Million)
Figure 32. Nanomedicine Market for Others, by Country, 2020-2030 ($ Million)
Figure 33. Nanomedicine Market Segmentation, by Modality
Figure 34. Nanomedicine Market for Treatments, by Country, 2020-2030 ($ Million)
Figure 35. Nanomedicine Market for Diagnostics, by Country, 2020-2030 ($ Million)
Figure 36. Abbott Laboratories: Net Sales, 2018-2020 ($ Million)
Figure 37. Abbott Laboratories: Revenue Share, by Segment, 2020 (%)
Figure 38. Abbott Laboratories: Revenue Share, by Region, 2020 (%)
Figure 39. Diasorin S. P. A: Net Sales, 2018-2020 ($ Million)
Figure 40. Diasorin S. P. A: Revenue Share, by Segment, 2020 (%)
Figure 41. Diasorin S. P. A: Revenue Share, by Region, 2020 (%)
Figure 42. General Electric Company: Net Sales, 2018-2020 ($ Million)
Figure 43. General Electric Company: Revenue Share, by Segment, 2020 (%)
Figure 44. General Electric Company: Revenue Share, by Region, 2020 (%)
Figure 45. Invitae Corporation: Net Sales, 2018-2020 ($ Million)
Figure 46. Invitae Corporation: Revenue Share, by Segment, 2020 (%)
Figure 47. Invitae Corporation: Revenue Share, by Region, 2020 (%)
Figure 48. Johnson & Johnson: Net Sales, 2018-2020 ($ Million)
Figure 49. Johnson & Johnson: Revenue Share, by Segment, 2020 (%)
Figure 50. Johnson & Johnson: Revenue Share, by Region, 2020 (%)
Figure 51. Leadiant Biosciences, Inc: Net Sales, 2018-2020 ($ Million)
Figure 52. Leadiant Biosciences, Inc: Revenue Share, by Segment, 2020 (%)
Figure 53. Leadiant Biosciences, Inc: Revenue Share, by Region, 2020 (%)
Figure 54. Mallinckrodt plc: Net Sales, 2018-2020 ($ Million)
Figure 55. Mallinckrodt plc: Revenue Share, by Segment, 2020 (%)
Figure 56. Mallinckrodt plc: Revenue Share, by Region, 2020 (%)
Figure 57. Merck & Co. Inc: Net Sales, 2018-2020 ($ Million)
Figure 58. Merck & Co. Inc: Revenue Share, by Segment, 2020 (%)
Figure 59. Merck & Co. Inc: Revenue Share, by Region, 2020 (%)
Figure 60. Pfizer, Inc: Net Sales, 2018-2020 ($ Million)
Figure 61. Pfizer, Inc: Revenue Share, by Segment, 2020 (%)
Figure 62. Pfizer, Inc: Revenue Share, by Region, 2020 (%)
Figure 63. Teva Pharmaceutical Industries Limited: Net Sales, 2018-2020 ($ Million)
Figure 64. Teva Pharmaceutical Industries Limited: Revenue Share, by Segment, 2020 (%)
Figure 65. Teva Pharmaceutical Industries Limited: Revenue Share, by Region, 2020 (%)

Executive Summary

According to a new report titled, “Nanomedicine Market by Modality, Application, and Indication: Global Opportunity Analysis and Industry Forecast, 2021–2030, the global nanomedicine market size was valued at $171,695.33 million in 2020, and is projected to reach $393,046.52 million by 2030, registering a CAGR of 9.2% from 2021 to 2030.

Nanomedicine is an application of nanotechnology that deals in prevention & treatment of diseases in humans. This technology uses sub micrometer-sized particles for diagnosis, treatment, and prevention of diseases. Nanomedicines are advantageous over generic drugs in several aspects such as they help to reduce renal excretion, improve ability of drugs to accumulate at pathological sites, and enhance therapeutic index of drugs. Thus, nanomedicine is used in a wide range of applications that include aerospace materials, cosmetics, and medicine.

The major factors that drive growth of the nanomedicine market are increase in development of nanotechnology-based drugs, advantages of nanomedicine in various healthcare applications, and growth in need for therapies with fewer side effects. However, long approval process and risks associated with nanomedicine (environmental impacts) are expected to hinder the market growth. Conversely, growth of healthcare facilities in emerging economies are expected to offer lucrative opportunities for growth of the market.

Coronavirus (COVID-19) was discovered in late December in Hubei province of Wuhan city in China. The disease is caused by a virus, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted among humans. Amidst the initial outbreak of COVID-19, the outlook for the nanomedicine industry has changed significantly. The COVID-19 pandemic led to significant increase in demand for nanomedicines for treatment of various diseases. The application of nanomedicine offered new opportunities for development of novel products for prevention, diagnosis, and treatment of COVID-19 virus and other viral infections. COVID-19 management was done with development of nano-based materials, which included disinfectants, personal protective equipment, diagnostic systems, and nanocarrier systems for treatment and vaccine development. This impacted the market with increase in demand for nanomedicines. Overall, the impact of COVID-19 on the nanomedicine market was recorded to be fairly positive. This was attributed to increase in demand for nanomedicines in the treatment of cancer like diseases. Moreover, market players have experienced the rise in investment in materials and resources, owing to increase in research and development activities of nanomedicines in all regions.

The nanomedicine market is segmented on the basis of modality, application, indication, and region. On the basis of modality, the market is segmented into diagnostics and treatment. On the basis of application, it is segmented into drug delivery, diagnostic imaging, vaccines, regenerative medicine, implants, and others. On the basis of indication, it is segmented into clinical oncology, infectious diseases, clinical cardiology, orthopedics, neurology, urology, ophthalmology, immunology and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

By modality, the treatment segment was the major contributor to the global market in 2020, and is anticipated to remain dominant during the forecast period, owing to technological advancements in the nanomedicines, increase in adoption of nanomedicines, rise in incidence rate of chronic diseases, and increase in number of advanced & effective product launches.

By application, the global nanomedicine market is classified into drug delivery, diagnostic imaging, vaccines, regenerative medicine, implants, and others. The drug delivery segment was the major contributor to the global market in 2020, and is anticipated to remain dominant during the forecast period, owing to increase in prevalence of diseases such as cancer and COVID-19 virus and increase in awareness regarding applications of nanomedicines.

On the basis of indication, the global nanomedicine market is classified into clinical oncology, infectious diseases, clinical cardiology, orthopedics, neurology, urology, ophthalmology, immunology and others. The clinical oncology segment was the major contributor to the global market in 2020, and is anticipated to remain dominant during the forecast period, owing to surge in number of oncology diseases and increase disposable income.

North America accounted for major share of the global nanomedicine market share in 2020, and is expected to remain dominant throughout the forecast period. This is attributed to increase in number of lethal diseases, surge in demand for nanomedicines, availability of advanced healthcare facilities with trained medical professionals, rise in number of R&D activities along with large presence of key players, and surge in investment made by governments in the healthcare system. However, Asia-Pacific is expected to experience the highest growth rate during the forecast period. Moreover, Japan and China are expected to grow at high CAGR in Asia-Pacific nanomedicine market majorly owing to improvement in healthcare infrastructure, rise in number of hospitals equipped with advanced instruments, development of the R&D sector, rise in healthcare reforms, and technological advancements in the field of nanomedicines.

Key Findings Of Study

• On the basis of modality, the treatment segment held majority share in the global market in 2020
• On the basis of application, the drug delivery segment held majority share in the global nanomedicine market in 2020
• On the basis of indication, the clinical oncology segment held majority share in the global market in 2020
• Region wise, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 112% during the forecast period

Companies Mentioned

• Abbott Laboratories
• DiaSorin S.p.A.
• General Electric Company
• Invitae Corporation
• Johnson & Johnson
• Leadient BioSciences Inc.
• Mallinckrodt plc
• Merck & Co., Inc.
• Pfizer Inc.
• Teva Pharmaceuticals Ltd.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

• Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
• Scientific and technical writings for product information and related preemptions
• Regional government and statistical databases for macro analysis
• Authentic news articles and other related releases for market evaluation
• Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.